Clinicians are Addressing the CBD Safety Epidemic.
As 2019 drew to a close, the CBD mislabeling epidemic in the USA was becoming worse than the 2015 University of Pennsylvania findings of 78%, with a Leafly study of 47 products suggesting mislabeling at 87% when a +/-5% standard deviation was applied.
Courageous clinicians like Dr. Daniel Pompa responded with sobering advice cautioning clinicians and patients to recognize that CBD has great promise healing cells and supporting homeostasis while insisting the current state of the industry is fraught with risk because of insufficient supply-chain regulations and absence of thorough scientific standards and transparent independent testing.
Doctors seeking to do no harm with CBD care need to be extremely careful.
Epidemic Answered with Clinician-Grade CBD Care from Endourage
In 2020 Endourage was introduced to the US market as distinctive and compelling to clinicians specifically because it was founded by clinicians for clinicians and patients, and it is one of the only companies that meets the Clinician-Grade Standard for safety and quality.
Formulations are created collaboratively by researchers and practitioners who bring decades of licensed medical experience to the process of delivering Complete Spectrum products that meet the high standards that clinicians expect.
Every clinician and patient can verify Clinician-Grade Safety and Quality on every label of every Endourage product.